A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder

Journal of Clinical Psychopharmacology

Volumn 23, Issue 3, 2003, Pages 240-249

  Feltner, Douglas E ^a   Crockatt, Jerri G ^a   Dubovsky, Steven J ^b   Cohn, Cal K ^c   Shrivastava, Ram K ^d   Targum, Steven D ^e   Liu Dumaw, Maria ^a   Carter, Cathryn M ^a   Pande, Atul C ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Fein Jennings Clinic Incorporated   (United States)

^d Eastside Compreh Medical Services   (United States)

^e Clinical Studies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; PLACEBO; PREGABALIN;

ACCIDENT; ADULT; AGED; AMBLYOPIA; AMNESIA; ARTICLE; ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HEADACHE; HUMAN; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; MANIA; MEMORY DISORDER; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; VERTIGO; VISUAL IMPAIRMENT; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 0038722338     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000084032.22282.ff     Document Type: Article

References (38)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Yonkers KA, Warshaw MG, Massion AO, et al. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry. 1996; 168: 308-313.
3. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:355-364.
4. DuPont RL, Rice DP, Miller LS, et al. Economic costs of anxiety disorders. Anxiety. 1996;2:167-172.
5. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60:427-435.
6. Connor KM, Davidson JRT. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry. 1998; 44:1286-1294.
7. Lader MH, Bond AJ. Interaction of pharmacological and psychological treatments of anxiety. Br J Psychiatry. 1998;173(Suppl 34):42-48.
8. van Laar M, Volkerts ER, van Willigenburg APP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol. 1992;12:86-95.
9. Rickels K, Schweizer E, Case WG, et al. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47:899-907.
10. Moller HJ. Effectiveness and safety of benzodiazepines. J Clin Psychopharmacol. 1999;19(Suppl 2):2S-11S.
11. Laakmann G, Schule C, Lorkowski G, et al. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology. 1998;136:357-366.
12. DeMartinis N, Rynn M, Rickels K, et al. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2000;61:91-94.
13. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997;95: 444-450.
14. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968-974.
15. Davidson JRT, Dupont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60: 528-535.
16. Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry. 1999;60(Suppl 22): 23-28.
17. Ellison JM. Antidepressant-induced sexual dysfunction: review, classification, and suggestions for treatment. Harvard Rev Psychiatry. 1998;6:177-189.
18. Kennedy SH, Eisfeld BS, Dickens SE, et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000;61:276-281.
19. Kinsora Jr JJ, Serpa KA, Snyder BJ, et al. Anxiolytic-like effects of pregabalin. Soc Neuroscience Abst. 1999;25:1319.
20. Taylor CP, Vartanian MG. Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models. Epilepsia. 1997;38(Suppl 8):35.
21. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002; 42(2):229-236.
22. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997;12:232-241.
23. Lipman R, Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer R, Klein DL, eds. Evaluation of the Psychological Therapies. Baltimore: Johns Hopkins University Press; 1976.
24. Raskin A, Schulterbrandt J, Reatig N, et al. Replication of factors of psychopathology in interview, ward behaviour and self report ratings of hospitalized depressives. J Nerv Ment Dis. 1969;148:87-98.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology. Publication (ADM) 76-338. Washington, DC: Department of Health, Education and Welfare; 1976;217-22.
26. Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999;67:716-722.
27. Sankar R, Wasterlain CG. Is the devil we know the lesser of 2 evils? Vigabatrin and visual fields. Neurology. 1999;52:1537-1538.
28. SAS/Stat User's Guide: Volumes 1 and 2, Version 6.0. Cary, North Carolina: SAS Institute; 1989.
29. Neter J, Wasserman W, Kutner MH. Applied Linear Statistical Models. Boston, Massachusetts: Irwin; 1990:861-898.
30. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988:800-802.
31. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 4th ed. Washington, DC: Department of Health and Human Services, Food and Drug Administration; 1996.
32. Rickels KR, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. Arch Gen Psychiatry. 1993; 50:884-895.
33. Kessler RC, DuPont RL, Berglund P, et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999;156:1915-1923.
34. Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl. 1998;393:6-11.
35. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708-713.
36. Rickels K, Schweizer E, Garcia-Espana F, et al. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology. 1999;141:1-5.
37. Schweizer E, Rickels K, Case WG, et al. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48: 448-452.
38. Schweizer E, Case WG, Garcia-Espana F, et al. Progesterone coadministration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology. 1995;117:424-429.